{
    "clinical_study": {
        "@rank": "102631", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: BMS-663068+DRV/RTV", 
                "arm_group_type": "Experimental", 
                "description": "Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26\nTablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16"
            }, 
            {
                "arm_group_label": "Cohort 2: BMS-663068+ETR", 
                "arm_group_type": "Experimental", 
                "description": "Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26\nTablet ETR 200mg orally orally twice daily on days 7-16"
            }, 
            {
                "arm_group_label": "Cohort 3: BMS-663068+DRV/RTV+ETR", 
                "arm_group_type": "Experimental", 
                "description": "Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26\nTablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if there is an interaction in healthy subjects\n      taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine."
        }, 
        "brief_title": "DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV/AIDS", 
        "detailed_description": {
            "textblock": "Brief title: drug-drug interaction (DDI)\n\n      Primary Purpose: Other : Phase 1 Clinical Pharmacology drug interaction study in healthy\n      subjects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Healthy subjects with no clinically significant deviation from normal in medical\n             history, physical examination findings, 12-lead ECG measurements, and clinical\n             laboratory tests\n\n          -  Women of childbearing potential (WOCBP) allowed. Must be practicing highly effective\n             methods of contraception\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical condition\n\n          -  Unable to tolerate oral medications\n\n          -  Inability to be venipunctured and/or tolerate venous access\n\n          -  Current or recent  (within 3 months of dosing) gastrointestinal disease\n\n          -  Abnormal liver function test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063360", 
            "org_study_id": "AI438-020"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1: BMS-663068+DRV/RTV", 
                    "Cohort 2: BMS-663068+ETR", 
                    "Cohort 3: BMS-663068+DRV/RTV+ETR"
                ], 
                "intervention_name": "BMS-663068", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1: BMS-663068+DRV/RTV", 
                    "Cohort 3: BMS-663068+DRV/RTV+ETR"
                ], 
                "intervention_name": "Darunavir (DRV)", 
                "intervention_type": "Drug", 
                "other_name": "Prezista"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1: BMS-663068+DRV/RTV", 
                    "Cohort 3: BMS-663068+DRV/RTV+ETR"
                ], 
                "intervention_name": "Ritonavir (RTV)", 
                "intervention_type": "Drug", 
                "other_name": "Norvir"
            }, 
            {
                "arm_group_label": [
                    "Cohort 2: BMS-663068+ETR", 
                    "Cohort 3: BMS-663068+DRV/RTV+ETR"
                ], 
                "intervention_name": "Etravirine (ETR)", 
                "intervention_type": "Drug", 
                "other_name": "Intelence"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ritonavir", 
                "Darunavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 13, 2014", 
        "number_of_arms": "3", 
        "official_title": "Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) of BMS-626529", 
                "safety_issue": "No", 
                "time_frame": "20 timepoints up to day 26"
            }, 
            {
                "measure": "Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529", 
                "safety_issue": "No", 
                "time_frame": "20 timepoints up to day 26"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063360"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) for BMS-626529, DRV, RTV, and ETR", 
                "safety_issue": "No", 
                "time_frame": "Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)"
            }, 
            {
                "measure": "Concentration at 12 hours (C12) for BMS-626529, DRV, RTV, and ETR", 
                "safety_issue": "No", 
                "time_frame": "Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)"
            }, 
            {
                "measure": "Trough observed plasma concentration (Ctrough) for BMS-626529, DRV, RTV, and ETR", 
                "safety_issue": "No", 
                "time_frame": "Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)"
            }, 
            {
                "measure": "Cmax for DRV, RTV, and ETR", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 26 day"
            }, 
            {
                "measure": "AUC(TAU) for DRV, RTV, and ETR", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 26 day"
            }, 
            {
                "measure": "Safety and tolerability endpoints include incidence of adverse event (AEs), serious adverse event (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 27"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}